Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 230 Published: June 30, 2022 Report Code: GDGMDHC22206IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis – Drugs In Development, 2022, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 21, 12, 2, 35 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).

– The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • AKSO Biopharmaceutical Inc

    Alexion Pharmaceuticals Inc

    Algomedix Inc

    Alnylam Pharmaceuticals Inc

    Amyndas Pharmaceuticals LLC

    Anagenics Ltd

    Angion Biomedica Corp

    Apellis Pharmaceuticals Inc

    Argenx SE

    Arrowhead Pharmaceuticals Inc

    Bayer AG

    BioCryst Pharmaceuticals Inc

    Biogen Inc

    Boehringer Ingelheim International GmbH

    Cabaletta Bio Inc

    Calliditas Therapeutics AB

    Ceptur Therapeutics Inc

    Certa Therapeutics Pty Ltd

    ChemoCentryx Inc

    Chinook Therapeutics Inc

    Coegin Pharma AS

    Cytodesign Inc

    Delta 4 GmbH

    DiaMedica Therapeutics Inc

    Dimerix Ltd

    Eledon Pharmaceuticals Inc

    Eli Lilly and Co

    Ergon Pharmaceuticals LLC

    Generian Pharmaceuticals Inc

    Goldfinch Bio Inc

    HanAll Biopharma Co Ltd

    Horizon Therapeutics Plc

    IGAN Biosciences Inc

    ImmunoWork LLC

    Inmagene Biopharmaceuticals Ltd

    InSilico Medicine

    Integral Molecular Inc

    INVENT Pharmaceuticals Inc

    Ionis Pharmaceuticals Inc

    Jiangsu Hengrui Medicine Co Ltd

    KeyMed Biosciences Inc

    Mallinckrodt Plc

    MorphoSys AG

    Novartis AG

    NovelMed Therapeutics Inc

    Oak Hill Bio Inc

    Omeros Corp

    Oraxion Therapeutics Inc

    Pfizer Inc

    PlateletBio

    Polyneuron Pharmaceuticals AG

    Puretech Health Plc

    Ra Pharmaceuticals Inc

    Reata Pharmaceuticals Inc

    RemeGen Co Ltd

    River 3 Renal Corp

    Rohto Pharmaceutical Co Ltd

    Shanghai Alebund Pharmaceuticals Ltd

    Shenzhen Evergreen Therapeutics Co Ltd

    Slate Bio Inc

    Sujana Biotech

  • LLC

    Surrozen Inc

    Takeda Pharmaceutical Co Ltd

    Transcenta Holding Ltd

    Travere Therapeutics Inc

    Vera Therapeutics Inc

    Vertex Pharmaceuticals Inc

    Visterra Inc

    Wuhan LL Science and Technology Development Co Ltd

    ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glomerulonephritis – Overview

Glomerulonephritis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Glomerulonephritis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glomerulonephritis – Companies Involved in Therapeutics Development

Glomerulonephritis – Drug Profiles

Glomerulonephritis – Dormant Projects

Glomerulonephritis – Discontinued Products

Glomerulonephritis – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Glomerulonephritis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Target, 2022 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Glomerulonephritis – Pipeline by AKSO Biopharmaceutical Inc, 2022

Glomerulonephritis – Pipeline by Alexion Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by Algomedix Inc, 2022

Glomerulonephritis – Pipeline by Alnylam Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by Amyndas Pharmaceuticals LLC, 2022

Glomerulonephritis – Pipeline by Anagenics Ltd, 2022

Glomerulonephritis – Pipeline by Angion Biomedica Corp, 2022

Glomerulonephritis – Pipeline by Apellis Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by Argenx SE, 2022

Glomerulonephritis – Pipeline by Arrowhead Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by Bayer AG, 2022

Glomerulonephritis – Pipeline by BioCryst Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by Biogen Inc, 2022

Glomerulonephritis – Pipeline by Boehringer Ingelheim International GmbH, 2022

Glomerulonephritis – Pipeline by Cabaletta Bio Inc, 2022

Glomerulonephritis – Pipeline by Calliditas Therapeutics AB, 2022

Glomerulonephritis – Pipeline by Ceptur Therapeutics Inc, 2022

Glomerulonephritis – Pipeline by Certa Therapeutics Pty Ltd, 2022

Glomerulonephritis – Pipeline by ChemoCentryx Inc, 2022

Glomerulonephritis – Pipeline by Chinook Therapeutics Inc, 2022

Glomerulonephritis – Pipeline by Coegin Pharma AS, 2022

Glomerulonephritis – Pipeline by Cytodesign Inc, 2022

Glomerulonephritis – Pipeline by Delta 4 GmbH, 2022

Glomerulonephritis – Pipeline by DiaMedica Therapeutics Inc, 2022

Glomerulonephritis – Pipeline by Dimerix Ltd, 2022

Glomerulonephritis – Pipeline by Eledon Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by Eli Lilly and Co, 2022

Glomerulonephritis – Pipeline by Ergon Pharmaceuticals LLC, 2022

Glomerulonephritis – Pipeline by Generian Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by Goldfinch Bio Inc, 2022

Glomerulonephritis – Pipeline by HanAll Biopharma Co Ltd, 2022

Glomerulonephritis – Pipeline by Horizon Therapeutics Plc, 2022

Glomerulonephritis – Pipeline by IGAN Biosciences Inc, 2022

Glomerulonephritis – Pipeline by ImmunoWork LLC, 2022

Glomerulonephritis – Pipeline by Inmagene Biopharmaceuticals Ltd, 2022

Glomerulonephritis – Pipeline by InSilico Medicine, 2022

Glomerulonephritis – Pipeline by Integral Molecular Inc, 2022

Glomerulonephritis – Pipeline by INVENT Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by Ionis Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Glomerulonephritis – Pipeline by KeyMed Biosciences Inc, 2022

Glomerulonephritis – Pipeline by Mallinckrodt Plc, 2022

Glomerulonephritis – Pipeline by MorphoSys AG, 2022

Glomerulonephritis – Pipeline by Novartis AG, 2022

Glomerulonephritis – Pipeline by NovelMed Therapeutics Inc, 2022

Glomerulonephritis – Pipeline by Oak Hill Bio Inc, 2022

Glomerulonephritis – Pipeline by Omeros Corp, 2022

Glomerulonephritis – Pipeline by Oraxion Therapeutics Inc, 2022

Glomerulonephritis – Pipeline by Pfizer Inc, 2022

Glomerulonephritis – Pipeline by PlateletBio, 2022

Glomerulonephritis – Pipeline by Polyneuron Pharmaceuticals AG, 2022

Glomerulonephritis – Pipeline by Puretech Health Plc, 2022

Glomerulonephritis – Pipeline by Ra Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by Reata Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by RemeGen Co Ltd, 2022

Glomerulonephritis – Pipeline by River 3 Renal Corp, 2022

Glomerulonephritis – Pipeline by Rohto Pharmaceutical Co Ltd, 2022

Glomerulonephritis – Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2022

Glomerulonephritis – Pipeline by Shenzhen Evergreen Therapeutics Co Ltd, 2022

Glomerulonephritis – Pipeline by Slate Bio Inc, 2022

Glomerulonephritis – Pipeline by Sujana Biotech, LLC, 2022

Glomerulonephritis – Pipeline by Surrozen Inc, 2022

Glomerulonephritis – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Glomerulonephritis – Pipeline by Transcenta Holding Ltd, 2022

Glomerulonephritis – Pipeline by Travere Therapeutics Inc, 2022

Glomerulonephritis – Pipeline by Vera Therapeutics Inc, 2022

Glomerulonephritis – Pipeline by Vertex Pharmaceuticals Inc, 2022

Glomerulonephritis – Pipeline by Visterra Inc, 2022

Glomerulonephritis – Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022

Glomerulonephritis – Pipeline by ZyVersa Therapeutics Inc, 2022

Glomerulonephritis – Dormant Projects, 2022

Glomerulonephritis – Dormant Projects, 2022 (Contd..2)

Glomerulonephritis – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Glomerulonephritis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.